Prelude Therapeutics announced FDA clearance for a Phase 1 study of oral degrader PRT13722 in HR+ breast cancer, with anticipated enrollment starting in Q4 2026. This regulatory milestone supports the company's specific approach to a validated oncology target, expanding its precision medicine pipeline.